Kevin Kelly, DO, Receives “Director’s Award for Impact” at Member Retreat

Congratulations to Wm. Kevin Kelly, DO, Professor of Medical Oncology and Director of the Division of Solid Tumor Oncology, for receiving the “Director’s Award for Impact” at the recent Sidney Kimmel Cancer Center at Jefferson Health (SKCC) Member Retreat, held at Citizens Bank Park in Philadelphia. Kelly, who is also the leader of the Prostate Cancer …


Knudsen and Kelly Receive NCI Funding

Two Sidney Kimmel Cancer Center investigators, Karen Knudsen, PhD, and Wm. Kevin Kelly, DO, have been awarded a new R01 grant from the National Cancer Institute to develop more effective therapeutic strategies for advanced prostate cancer. The project builds on previous discoveries from these investigators that identified specific cell cycle alterations in metastatic castrate-resistant prostate cancer and …


Bench to Bedside: How to Fast Track Targeted Cancer Drugs with Radiation into the Clinic

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy. The suggested strategic guidelines, published in the Journal of the National Cancer Institute in a recent commentary …


NCI Awards ‘Provocative Questions’ Grant to Thomas Jefferson University Researcher Scott Waldman

Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded one of the prestigious “Provocative Questions”  grants from the National Cancer Institute (NCI) , as part of the Institute’s ambitious program to tackle the “important but not obvious” questions in cancer to ensure no stone …


Jefferson Clinical Trial: Can a Cholesterol Drug Prevent Colon Cancer?

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute (NCI)-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer. Previous laboratory research and population studies have shown that patients taking statins, the class of drugs that lowers cholesterol, had fewer colon polyps, …